Navigation Links
InspireMD Reports Financial Results For Period Ended March 31, 2013
Date:5/8/2013

or the 1,114-patient trial, which will be conducted at 70 sites in the U.S. and Europe, will be Gregg Stone, MD, of the Cardiovascular Research Foundation in New York and Jose P.S. Henriques, MD, of the Academic Medical Center Amsterdam in The Netherlands.

Upcoming EventsInspireMD will host a symposium with key opinion leaders to review six month follow up data from the Company's multi-center MASTER trial of the MGuard Embolic Protection Stent.  The meeting will take place at the EuroPCR meeting in Paris, France on Thursday, May 23rd at 12:00pm Paris time. 

About Stenting and MGuard™ EPS™Standard stents were not engineered for heart attack patients. They were designed for treating stable angina patients whose occlusion is different from that of an occlusion in a heart attack patient.

In acute heart attack patients, the plaque or thrombus is unstable and often breaks up as the stent is implanted causing downstream blockages (some of which can be fatal) in a significant portion of heart attack patients.

The MGuard EPS is integrated with a precisely engineered micro net mesh that prevents the unstable arterial plaque and thrombus (clots) that caused the heart attack blockage from breaking off.

While offering superior performance relative to standard stents in STEMI patients with regard to ST segment resolution, the MGuard EPS requires no change in current physician practice - an important factor in promoting acceptance and general use in time-critical emergency settings.

About InspireMD, Inc.InspireMD is a medical device company focusing on the development and commercialization of its proprietary stent system technology, MGuard. InspireMD intends to pursue applications of this technology in coronary, carotid and peripheral artery procedures. InspireMD's common stock is quoted on the NYSE MKT under the ticker symbol NSPR.

MGuard EPS is CE Mark approved. It is not approved for sale in the
'/>"/>

SOURCE InspireMD, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. InspireMD Receives Approval From US Food and Drug Administration to Begin US Regulatory Trial
2. InspireMD Closes $25 Million Underwritten Public Offering
3. InspireMD Announces Pricing of Underwritten Public Offering of Common Stock and Listing on NYSE MKT
4. InspireMD Receives CE Mark Approval for Carotid Embolic Protection Stent
5. InspireMD Files Amended Registration Statement for Proposed Public Offering of Common Stock
6. InspireMD Reports Results for Period Ended Dec. 31, 2012
7. InspireMD to Discuss MGuard(TM) and the MASTER Randomized Trial Results at the ICI 2012 Meeting
8. Positive Results of InspireMDs MASTER Trial to be Published on November 6 in Journal of American College of Cardiology
9. InspireMD Reports Results For Period Ending Sept. 30, 2012
10. InspireMD Announces Positive Results From MGuard(TM) Stent MASTER Trial for Emergency Treatment of Heart Attack Patients
11. InspireMD to Present at Harvard Investors Group on June 27 in New York
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... Feffer LLP ( www.hfesq.com ) is investigating potential claims ... or the "Company") (NASDAQ: ADXS ), concerning ... shareholders. On January 21, 2015, an article ... had misrepresented the clinical data for its ADXS-HPV drug ...
(Date:1/23/2015)... 23, 2015  Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT), announced that ... of Lixte,s lead compound, LB‑100, is being conducted, has been ... S. Kovach , M.D., the founder and President of Lixte, ... at a single site. Accrual of patients, however, was slower ...
(Date:1/23/2015)... , Jan. 23, 2015 Gem Pharmaceuticals announced today ... been enrolled into the Company,s Phase 2 clinical trial. ... of Gem,s lead compound, GPX-150 (an investigational medication), in ... metastatic disease. Logo - http://photos.prnewswire.com/prnh/20150123/170966LOGO ...
Breaking Medicine Technology:Harwood Feffer LLP Announces Investigation of Advaxis, Inc. 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 3Gem Pharmaceuticals Announces Enrollment of Initial Patients in its Phase 2 Clinical Trial to Assess the Efficacy and Safety of GPX-150 in Sarcoma Patients 2
... 2012  BioParadox, Inc., a regenerative medicine company pioneering ... a strategic alliance with Fogarty Institute for Innovation.  ... working with the Fogarty Institute for Innovation known ... patients with challenging problems.  The Fogarty Institute,s unique ...
... 2, 2012 Synthetic Genomics, Inc. (SGI), a ... to solve a variety of global needs, and ... in production and supply of oligonucleotides, today jointly ... to manufacture, market, and commercialize small synthetic gene ...
Cached Medicine Technology:BioParadox Announces Partnership with Fogarty Institute for Innovation 2Synthetic Genomics, Inc. and Integrated DNA Technologies, Inc. Sign Agreement to Manufacture, Market, and Commercialize Small Synthetic Gene Products Using SGI Technology 2
(Date:1/22/2015)... (PRWEB) January 22, 2015 The City of West ... 10 a.m., to commemorate the 42nd anniversary of the Supreme Court ... , “It’s been 42 years since the Roe vs. Wade decision ... still as present as ever,” said City of West Hollywood Councilmember ...
(Date:1/22/2015)... VogueQueen is a seasoned and trusted leader who ... are thrilled to have it lead the wedding dress industry ... of prom dresses for the global market. , “The CEO ... and he focuses on continuing the goal of operational excellence ...
(Date:1/22/2015)... AngelWeddingDress, the premier women’s dress supplier, has recently released ... website of AngelWeddingDress.com to find more details. , ... for a bridal party. AngelWeddingDress offers a variety of ... maternity wedding dresses are specially designed for 2015. , ...
(Date:1/22/2015)... Thousand of GranuFlo lawsuits ( http://www.granuflolawsuit2014.com/ ... GranuFlo and NaturaLyte dialysis concentrates continue to move forward ... Court, District of Massachusetts, Bernstein Liebhard LLP reports. According ... remanded a case filed by the state of Louisiana ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Joan Lunden, ... keynote speaker at the upcoming 32nd Annual Miami ... Physicians’ Education Resource®, LLC (PER®) , shares that ... have gone undetected if she had not followed up ...
Breaking Medicine News(10 mins):Health News:VogueQueen Unveils New Designs of Prom Dresses for 2015 2Health News:AngelWeddingDress Has Recently Released Its Collection Of 2015 Maternity Wedding Dresses 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 5Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 6
... CUR, QUEBEC CITY, June 3 /PRNewswire-FirstCall/ - Two ... the detection of prostate cancer,and GCC for the staging ... part of the growing trend to molecular diagnostics., ... the 34th,Annual International Clinical Ligand Assay Society Meeting, held ...
... with whatever they could find, - Needs remain desperate for ... 250,000 survivors to date, but access ... challenges remain, YANGON, ... Nargis, many affected communities in Myanmar,s,Irrawaddy Delta are managing to survive and ...
... Personal Trainers For Peak ... Performance, LOS ANGELES, June 2 ... and Cher, now the,Pussycat Dolls are working out with Bally. On the verge ... video for,their hot new single "When I Grow Up," the Pussycat Dolls are ...
... Will Fund Chicago Latino Outreach Program and National Latino ... ... American Diabetes,Association (ADA) was recently awarded a $450,000 grant from Abbott ... Latino,Outreach Toolkit. Diabetes is an urgent health problem in the Latino,community. ...
... N.Y., June 2 Gentiva Health,Services, Inc. (Nasdaq: ... home health services, announced today that it has ... largest home health,providers, for $12 million in cash. ... facility., PHHC, first established by a group ...
... the risk, study finds , , MONDAY, June 2 (HealthDay News) ... increased risk for cancer recurrence, a Dana-Farber Cancer Institute study ... stage III colon cancer, and found that those with a ... years smoking times packs per day) were up to 22 ...
Cached Medicine News:Health News:DiagnoCure's molecular diagnostic tests - PCA3 and GCC - discussed at scientific meetings 2Health News:DiagnoCure's molecular diagnostic tests - PCA3 and GCC - discussed at scientific meetings 3Health News:Myanmar One Month Later: Delta Communities Surviving on Resilience 2Health News:Pussycat Dolls Shape Up With Bally Total Fitness 2Health News:American Diabetes Association Receives $450,000 Grant From Abbott Fund for Latino Community Initiatives 2Health News:Gentiva(R) Health Services Acquires Leading Colorado Home Health Provider 2Health News:Gentiva(R) Health Services Acquires Leading Colorado Home Health Provider 3Health News:Smokers With Colon Cancer Face High Recurrence Risk 2
... Slit Lamp features easy-to-use controls to help ... to a halogen bulb that gives up ... with powers of 10X and 16X, the ... accepts commercially available C-mount cameras, allowing physicians ...
... PachPen uses state-of-the-art waveform analysis ... at a 65MHz rate to ... stores and averages nine measurements ... pen fits comfortably into the ...
Perfect for loading small volume samples onto agarose and polyacrylamide gels....
1000 L, Bulk Recommended for 500 and 1000 L pipettes...
Medicine Products: